Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?

Executive Summary

Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.

Advertisement

Related Content

Drug Pricing: With "Value" Debate In Full Swing, ICER’s Influence Grows
Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
The Clinton Drug Price Board, 23 Years Later
Medicare Cuts Could Come From HHS In 2019 With No IPAB In Sight
Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel